>Or does hiring a marketing firm AND IR specialist get the sentiment out of the way that is "in the way" according to this post by RFJ???<
A properly constructed publications/communications plan could double or triple the value of this company, and it wouldn't cost Repros more than $600K over two years for say 12 reviews, 4-6 primary articles, abstracts/posters at every major meeting, a speaker's program, and strategic oversight and platform/message development.
The keys for shaping the Androxal market, just off hand, include:
1) Communicating the novel MOA of the drug
2) Highlighting the limitations of current agents, including mode of administration and the drawbacks of supranormal testosterone levels
3) Identifying the need for testosterone therapy in general
4) Promoting the safety and efficacy of the drug in restoring testosterone levels
The keys for shaping the Proellex market (again just off hand)
1) Highlighting the MOA of the drug and build on the abundant data that shows this class of drugs works
2) Identifying the urgent need for new therapies for endometriosis and uterine fibroids
3) Promoting the safety and efficacy of the drug in the core proposed indications
3) Communicating potential uses beyond the core proposed indications
You shape the market by developing a platform based on the above and identifying consistent messaging that is used in all communications. Then you build a publication program that identifies which reviews and primaries will be written, when and where they will be submitted, and when and where the abstracts and posters will appear. You can also build a core advocacy group of physicians who believe in the potential for the products, and have them guide the agency in developing a speaker's presentation, which is then used by the core advocacy group to build market excitement.
It's all really very simple. Such a program, as I said before--if properly executed--could really build awareness about both products both in the medical community, the investment community, and with potential partners. Plus given the low market cap of Repros, it could have a tremendous impact on shareholder value.
You've got to communicate the data--repeatedly--in peer-reviewed venues and at major meetings. Otherwise it's like a tree falling in the forest with nobody around to hear it.
